Literature DB >> 30361778

Restriction of drug transport by the tumor environment.

Rajender Nandigama1, Berin Upcin1, Bertal H Aktas2, Süleyman Ergün1, Erik Henke3.   

Abstract

As in the systemic treatment of any disease, it is crucial for anti-cancer drugs to reach their target at a sufficient that is a therapeutically effective dose. However, unlike normal organs, solid tumors have a tendency to be undersupplied and hypoxic. This not only leads to insufficient supply of oxygen and nutrients but also to inefficient transport of drugs into tumors. As a consequence, administered doses have to be raised, resulting in increased side effects and often premature termination of treatment. A better understanding of the mechanisms that hamper transport of drugs into tumors could lead to the development of auxiliary strategies aimed at increasing tumor drug delivery and accumulation and thereby improving the efficacy of anti-cancer drugs at our disposal. The tumor microenvironment (TME), i.e., its vasculature, stroma, extracellular matrix and immune environment affect the transport of drugs to the tumor and their distribution within the tumor tissue in various ways. In this review we will highlight the current research regarding the cellular and molecular mechanisms that remain as an obstacle towards an effective cancer therapy, and also focus on the various strategies to alter the TME to increase tumor drug exposure and thereby treatment efficacy.

Entities:  

Keywords:  Angiogenesis; Cancer; Chemotherapy; Drug distribution; Extracellular matrix; Tumor microenvironment

Mesh:

Substances:

Year:  2018        PMID: 30361778     DOI: 10.1007/s00418-018-1744-z

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  179 in total

1.  Absolute quantification of [(11)C]docetaxel kinetics in lung cancer patients using positron emission tomography.

Authors:  Astrid A M van der Veldt; Mark Lubberink; Henri N Greuter; Emile F I Comans; Gerarda J M Herder; Maqsood Yaqub; Robert C Schuit; Arthur van Lingen; S Nafees Rizvi; Martien P J Mooijer; Anneloes Y Rijnders; Albert D Windhorst; Egbert F Smit; N Harry Hendrikse; Adriaan A Lammertsma
Journal:  Clin Cancer Res       Date:  2011-07-12       Impact factor: 12.531

2.  Lowering of tumoral interstitial fluid pressure by prostaglandin E(1) is paralleled by an increased uptake of (51)Cr-EDTA.

Authors:  K Rubin; M Sjöquist; A M Gustafsson; B Isaksson; G Salvessen; R K Reed
Journal:  Int J Cancer       Date:  2000-06-01       Impact factor: 7.396

3.  Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours.

Authors:  Shelly Zaffryar-Eilot; Derek Marshall; Tali Voloshin; Avinoam Bar-Zion; Rhyannon Spangler; Ofra Kessler; Haben Ghermazien; Vera Brekhman; Edith Suss-Toby; Dan Adam; Yuval Shaked; Victoria Smith; Gera Neufeld
Journal:  Carcinogenesis       Date:  2013-07-04       Impact factor: 4.944

4.  IL17 Promotes Mammary Tumor Progression by Changing the Behavior of Tumor Cells and Eliciting Tumorigenic Neutrophils Recruitment.

Authors:  Luciana Benevides; Denise Morais da Fonseca; Paula Barbim Donate; Daniel Guimarães Tiezzi; Daniel D De Carvalho; Jurandyr M de Andrade; Gislaine A Martins; João S Silva
Journal:  Cancer Res       Date:  2015-07-24       Impact factor: 12.701

5.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

6.  Cancer-Associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor Stroma.

Authors:  Daniela Pankova; Yulong Chen; Masahiko Terajima; Mark J Schliekelman; Brandi N Baird; Monica Fahrenholtz; Li Sun; Bartley J Gill; Tegy J Vadakkan; Min P Kim; Young-Ho Ahn; Jonathon D Roybal; Xin Liu; Edwin Roger Parra Cuentas; Jaime Rodriguez; Ignacio I Wistuba; Chad J Creighton; Don L Gibbons; John M Hicks; Mary E Dickinson; Jennifer L West; K Jane Grande-Allen; Samir M Hanash; Mitsuo Yamauchi; Jonathan M Kurie
Journal:  Mol Cancer Res       Date:  2015-12-02       Impact factor: 5.852

7.  Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress.

Authors:  Zachary T Schug; Barrie Peck; Dylan T Jones; Qifeng Zhang; Shaun Grosskurth; Israt S Alam; Louise M Goodwin; Elizabeth Smethurst; Susan Mason; Karen Blyth; Lynn McGarry; Daniel James; Emma Shanks; Gabriela Kalna; Rebecca E Saunders; Ming Jiang; Michael Howell; Francois Lassailly; May Zaw Thin; Bradley Spencer-Dene; Gordon Stamp; Niels J F van den Broek; Gillian Mackay; Vinay Bulusu; Jurre J Kamphorst; Saverio Tardito; David Strachan; Adrian L Harris; Eric O Aboagye; Susan E Critchlow; Michael J O Wakelam; Almut Schulze; Eyal Gottlieb
Journal:  Cancer Cell       Date:  2015-01-12       Impact factor: 31.743

Review 8.  Desmoplasia and chemoresistance in pancreatic cancer.

Authors:  Marvin Schober; Ralf Jesenofsky; Ralf Faissner; Cornelius Weidenauer; Wolfgang Hagmann; Patrick Michl; Rainer L Heuchel; Stephan L Haas; J-Matthias Löhr
Journal:  Cancers (Basel)       Date:  2014-10-21       Impact factor: 6.639

9.  Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors.

Authors:  Szilvia Torok; Melinda Rezeli; Olga Kelemen; Akos Vegvari; Kenichi Watanabe; Yutaka Sugihara; Anna Tisza; Timea Marton; Ildiko Kovacs; Jozsef Tovari; Viktoria Laszlo; Thomas H Helbich; Balazs Hegedus; Thomas Klikovits; Mir Alireza Hoda; Walter Klepetko; Sandor Paku; Gyorgy Marko-Varga; Balazs Dome
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

10.  Collagen prolyl hydroxylases are essential for breast cancer metastasis.

Authors:  Daniele M Gilkes; Pallavi Chaturvedi; Saumendra Bajpai; Carmen C Wong; Hong Wei; Stephen Pitcairn; Maimon E Hubbi; Denis Wirtz; Gregg L Semenza
Journal:  Cancer Res       Date:  2013-03-28       Impact factor: 12.701

View more
  3 in total

1.  In focus in HCB.

Authors:  Douglas J Taatjes; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2018-11-16       Impact factor: 4.304

2.  In focus in HCB.

Authors:  Douglas J Taatjes; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2020-05       Impact factor: 4.304

Review 3.  Cell-in-Cell Phenomenon and Its Relationship With Tumor Microenvironment and Tumor Progression: A Review.

Authors:  Xinlong Wang; Yilong Li; Jiating Li; Le Li; Hong Zhu; Hua Chen; Rui Kong; Gang Wang; Yongwei Wang; Jisheng Hu; Bei Sun
Journal:  Front Cell Dev Biol       Date:  2019-12-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.